Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 3/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6742014 | 0.88 | TSHR (0.48) | CHRM4TSHRPDE5ASTAT1BCDIN3D | |
| SCHEMBL6743539 | 0.85 | CCNB2 (0.47) | CHRM4TSHRPDE5ASTAT1MAPK1 | |
| SCHEMBL6739651 | 0.83 | KMT2A (0.47) | TSHRSTAT1MAPK1 | |
| SCHEMBL6746130 | 0.82 | ALPL (0.42) | CHRM4 | |
| SCHEMBL6742318 | 0.80 | MRGPRX1 (0.52) | STAT1MAPK1 | |
| SCHEMBL6739846 | 0.80 | SMN1; SMN2 (0.56) | TSHRSTAT1MAPK1 | |
| SCHEMBL6745666 | 0.77 | MAPT (0.45) | TSHRBCDIN3DMAPK1 | |
| SCHEMBL21075960 | 0.76 | CHRM4 (0.59) | CHRM4PDE5ASTAT1BCDIN3D | |
| SCHEMBL6746105 | 0.76 | MAPT (0.46) | — | |
| SCHEMBL6741661 | 0.76 | MAPT (0.41) | CHRM4TSHRKDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818642-B2 | CAMPYLOBACTER INFECTION TREATMENT | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040152714-A1 | Benzylaminopyrimidines | ALTANA PHARMA AG (DE) | 2004-08-05 | — | — | US | disclosed |
| EP-1395594-A1 | NEW BENZYLAMINOPYRIMIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094832-A1 | NEW BENZYLAMINOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152714-A1 | Benzylaminopyrimidines | DPYD, PGLS, TPMT | CHRM4 4860/4885TSHR 2503/4885PDE5A 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.